Lead Product(s) : Cannabidivarin
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Cannabics Pharmaceuticals Develops Novel Cannabis Formulation for the Treatment of Colon Cancer
Details : The company plans to examine the clinical safety and efficacy of the novel formulation which contains high concentrations of the cannabinoids CBDV and CBGA in a proprietary formulation.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 13, 2020
Lead Product(s) : Cannabidivarin
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2019
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Foundation for Prader-Willi Research | GW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
CBDV vs Placebo in Children and Adults up to Age 30 With Prader-Willi Syndrome (PWS)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 20, 2019
Lead Product(s) : Cannabidivarin
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Foundation for Prader-Willi Research | GW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : US Department of Defense | GW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Cannabidivarin (CBDV) vs. Placebo in Children With Autism Spectrum Disorder (ASD)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 28, 2017
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : US Department of Defense | GW Pharmaceutical
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GWP42006 in People With Focal Seizures - Part A
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 24, 2015
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of GWP42006 in People With Focal Seizures - Part B
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 19, 2015
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Safety and Tolerability of GWP42006 in Healthy Subjects
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 08, 2013
Lead Product(s) : Cannabidivarin
Therapeutic Area : Neurology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable